Amjevita (Adalimumab-atto): A Comprehensive Guide for Indian Patients

Understanding Amjevita (Adalimumab-atto) for Inflammatory Conditions Amjevita, with the active ingredient adalimumab-atto, is a prescription medication used to manage several inflammatory conditions. It belongs to a class of drugs known as TNF blockers, which work by reducing inflammation in the body. In India, Amjevita is available as a liquid solution that is injected under the skin. This guide aims to provide a clear and practical understanding of Amjevita for Indian patients, covering its uses, potential side effects, dosage, and comparisons with similar medications. What is Amjevita Used For? Amjevita is prescribed for adults and, in some cases, children to treat conditions characterized by chronic inflammation. These include: Rheumatoid Arthritis: A condition causing joint pain, swelling, and stiffness. Plaque Psoriasis: A skin condition leading to red, scaly patches. Crohn's Disease: An inflammatory bowel disease affecting the digestive tract. Ulcerative Colitis: Another inflammatory bowel disease affecting the large intestine. Hidradenitis Suppurativa: A chronic skin condition causing painful lumps under the skin. Juvenile Idiopathic Arthritis (JIA): In children aged 2 years and older, for moderately to severely active polyarticular JIA, which causes stiff, swollen, or painful joints. Uveitis: Inflammation of the eye. The specific use and dosage depend on the condition being treated and the patient's age and response to the medication. How Does Amjevita Work? Amjevita works by targeting and blocking a protein called tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is a key player in the inflammatory process. By inhibiting TNF-alpha, Amjevita helps to reduce inflammation, alleviate symptoms, and slow down the progression of certain diseases. Amjevita vs. Humira: Understanding Biosimilars Amjevita is a biosimilar of Humira (adalimumab). Biosimilar medications are highly similar to existing biologic drugs (like Humira) and have no clinically meaningful differences in terms of safety, purity, and potency. They are developed to offer similar therapeutic benefits at potentially a more accessible cost. While both Amjevita and Humira are approved for many of the same conditions, there might be slight differences in their approved indications for certain age groups or specific conditions. For instance, Amjevita is approved for ulcerative colitis, hidradenitis suppurativa, and uveitis in adults only, whereas Humira may have broader approvals in children for these conditions. It is crucial to discuss these nuances with your doctor. Dosage and Administration The dosage and schedule for Amjevita injections vary depending on the condition being treated: Plaque Psoriasis or Uveitis: An initial dose is given on day 1, followed by another dose on day 8. Subsequently, injections are administered every other week. Crohn's Disease, Hidradenitis Suppurativa, or Ulcerative Colitis: An initial dose is given on day 1, followed by doses on days 15 and 29. After that, injections are given every other week. For adults with these conditions, the first dose might be split over two days. Juvenile Idiopathic Arthritis (JIA): The dosage for children is determined by their weight and the severity of the condition. Amjevita is administered as a subcutaneous injection (under the skin). Your doctor or a healthcare professional will guide you on the correct injection technique. It is important to follow the prescribed schedule strictly. Potential Side Effects of Amjevita Like all medications, Amjevita can cause side effects. While serious side effects are not common, they can occur. It is vital to be aware of these potential risks: Common Side Effects: Injection site reactions (redness, itching, swelling, pain) Upper respiratory infections (cold symptoms) Headache Rash Nausea Serious Side Effects: Boxed Warning: Increased Risk of Cancer Amjevita carries a boxed warning regarding an increased risk of developing certain cancers, including lymphoma, leukemia, and skin cancer. Patients should be monitored closely for any signs of new or worsening cancer. Other serious side effects may include: Serious Infections: Amjevita can lower the body's ability to fight infections. Patients may be more susceptible to tuberculosis (TB), fungal infections, and other serious infections. It is crucial to inform your doctor if you have any signs of infection, such as fever, chills, cough, or fatigue. Allergic Reactions: Severe allergic reactions can occur. Symptoms may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Seek immediate medical attention if you experience these symptoms. Nervous System Problems: Rarely, Amjevita can cause nerve problems, such as multiple sclerosis, Guillain-Barré syndrome, or optic neuritis. Heart Failure: Amjevita may worsen existing heart failure. Blood Disorders: Low blood cell counts can occur. Lupus-like Syndrome: Symptoms may include chest pain, shortness of breath, joint pain, and rash on the cheeks or arms that worsens with sun exposure. Call your doctor immediately if you experience any serious side effects. If you believe you are having a medical emergency, call 911 or your local emergency number. When to Consult a Doctor It is essential to consult your doctor before starting Amjevita to discuss your medical history, including any existing infections, autoimmune diseases, heart conditions, or a history of cancer. You should also consult your doctor if: You develop signs of a new infection. You experience any severe or persistent side effects. You are pregnant, planning to become pregnant, or breastfeeding. You have any concerns or questions about the medication. You think you have received too much Amjevita. Contact your doctor or poison control center. If symptoms are severe, seek emergency medical help. Precautions and Warnings Screening for Infections: Before starting Amjevita, your doctor will likely screen you for tuberculosis (TB) and other infections. Vaccinations: Live vaccines should generally be avoided while taking Amjevita. Discuss your vaccination status with

In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.